Phase IA/IB Trial of Modulation of the Biological Response to Interleukin-2 (IL-2) With Bryostatin 1 (BRYO; NSC 339555)
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Bryostatin-1 (Primary) ; Interleukin-2 (Primary)
- Indications Malignant melanoma; Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- 05 Nov 2007 Status change
- 26 Sep 2005 New trial record.